| Name | Renalytix (Reg S) |
|---|---|
| Epic | RENX |
| Isin | GB00BYWL4Y04 |
| Industry | Medical Equipment and Services |
| Latest share price | 12.25p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £23.27 | Debt ratio | n/a |
| Shares in issue | 189.93 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -4912.19 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -31 | 52-week high / low | 6.75p / 50.40p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Renalytix (Reg S) |
|---|---|
| Address | 2 Leman Street, London, United Kingdom, E1W 9US |
| Telephone | |
| Website | http://www.renalytix.com/ |
| Director | Position |
|---|---|
| Mr James Renwick McCullough | CEO |
| Ms Catherine Coste | Non-Executive Director |
| Mr Erik Kristian Lium | Non-Executive Director |
| Mr Christopher H B Mills | Non-Executive Chairman |
| Mr Fergus Fleming | Chief Technical Officer |
| Assets $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Reporting date | 30/06/24 | 30/06/23 | 30/06/22 |
| Intangible asssets and goodwill | n/a | n/a | 14.02 |
| Investments and other non-current assets | 0.7 | 1.46 | 0.01 |
| Total non-current assets | 1.85 | 3.75 | 15.83 |
| Inventory / work in progress | n/a | n/a | 1.16 |
| Trade and other receivables | 0.72 | 0.78 | 0.9 |
| Cash and equivalents | 4.68 | 24.68 | 41.33 |
| Other current assets and asset held for resale | 0.72 | 1.42 | 4.04 |
| Total of all assets | 7.97 | 30.63 | 63.26 |
| Liabilities $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Short term liabilities | 11.49 | 16.14 | 12.2 |
| Long term liabilities | 4.33 | 7.53 | 7.88 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 15.83 | 23.66 | 20.09 |
| Net assets $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net assets | -7.85 | 6.97 | 43.17 |
| Equity $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Share capital | 0.48 | 0.29 | 0.24 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -211.78 | -178.32 | -52.96 |
| Share premium account | 204.89 | 186.46 | 85.44 |
| Total equity | -7.85 | 6.97 | 43.17 |
| Income $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -29.61 | -42.22 | -57.37 |
| Pre-tax profit | -33.45 | -45.6 | -49.63 |